Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00022295 · ClinicalTrials.gov registry record · Phase 1
Phenoxodiol in Treating Patients With Refractory Solid Tumors
A Phase 1 study, sponsored by Kazia Therapeutics Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT00022295 is a Phase 1 study that has completed, run by Kazia Therapeutics Limited. The registered enrollment target is 36 participants.
The verdict
NCT00022295, a Phase 1 study, has completed, sponsored by Kazia Therapeutics Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
RATIONALE: Phenoxodiol may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of phenoxodiol in treating patients who have refractory solid tumors.
Interventions
- DRUG idronoxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2001-08 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00022295
The ClinicalTrials.gov registry entry for NCT00022295 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kazia Therapeutics Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which idronoxil is the first listed.
NCT00022295 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00022295 about?
NCT00022295 is a clinical study titled "Phenoxodiol in Treating Patients With Refractory Solid Tumors". RATIONALE: Phenoxodiol may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I trial to study the effectiveness of phenoxodiol in treating patients who have refractory solid tumors.
What is the current status of trial NCT00022295?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2001-08. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00022295?
The interventions under investigation include: idronoxil (DRUG).
Who is sponsoring clinical trial NCT00022295?
This trial is sponsored by Kazia Therapeutics Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.